Approval Year
Substance Class |
Mixture
Created
by
admin
on
Edited
Thu Jul 06 08:07:10 UTC 2023
by
admin
on
Thu Jul 06 08:07:10 UTC 2023
|
Record UNII |
6D53G0FD0Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type | ||
---|---|---|---|
|
Alternative Definition |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 640.93
Created by
admin on Thu Jul 06 08:07:52 UTC 2023 , Edited by admin on Thu Jul 06 08:07:52 UTC 2023
|
||
|
CFR |
21 CFR 640.92
Created by
admin on Thu Jul 06 08:07:52 UTC 2023 , Edited by admin on Thu Jul 06 08:07:52 UTC 2023
|
||
|
CFR |
21 CFR 640.91
Created by
admin on Thu Jul 06 08:07:52 UTC 2023 , Edited by admin on Thu Jul 06 08:07:52 UTC 2023
|
||
|
CFR |
21 CFR 640.90
Created by
admin on Thu Jul 06 08:07:52 UTC 2023 , Edited by admin on Thu Jul 06 08:07:52 UTC 2023
|
||
|
CFR |
21 CFR 640.94
Created by
admin on Thu Jul 06 08:07:52 UTC 2023 , Edited by admin on Thu Jul 06 08:07:52 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6D53G0FD0Z
Created by
admin on Thu Jul 06 08:07:52 UTC 2023 , Edited by admin on Thu Jul 06 08:07:52 UTC 2023
|
PRIMARY | |||
|
DB13968
Created by
admin on Thu Jul 06 08:07:52 UTC 2023 , Edited by admin on Thu Jul 06 08:07:52 UTC 2023
|
PRIMARY | |||
|
33835
Created by
admin on Thu Jul 06 08:07:52 UTC 2023 , Edited by admin on Thu Jul 06 08:07:52 UTC 2023
|
PRIMARY | RxNorm | ||
|
6D53G0FD0Z
Created by
admin on Thu Jul 06 08:07:52 UTC 2023 , Edited by admin on Thu Jul 06 08:07:52 UTC 2023
|
PRIMARY | |||
|
SUB127871
Created by
admin on Thu Jul 06 08:07:52 UTC 2023 , Edited by admin on Thu Jul 06 08:07:52 UTC 2023
|
PRIMARY |
All of the following components must be present:
UNSPECIFIED SUBSTANCE
(not present in database)
Related Record | Type | Details | ||
---|---|---|---|---|
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
GLE is approximately 97.5% bound to human plasma proteins independent of concentration from 0.1 to 30 μM (800 to 25,200 ng/mL).
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
Plasma protein binding for valdecoxib is about 98% over the concentration range (21-2384 ng/mL).
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
Plasma protein binding of relugolix is 68 to 71%, primarily to albumin and to a lesser extent to α1-acid glycoprotein.
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
Primarily to albumin
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
with no concentration dependence over the range of 100–500 ng/mL
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
In vitro, human plasma protein binding was determined to be low (<18%) across a range of peramivir concentrations (10-1000 ng/mL) with no partitioning into red blood cells (Study DM99362).
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
The high affinity binding protein for amprenavir is alpha1-acid glycoprotein (AAG).
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
Protein binding of tepotinib is 98% and is independent of drug concentration at clinically relevant exposures.
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
In vitro plasma protein binding of lonafarnib was greater than or equal to 99% over the concentration range between 0.5 to 40.0 μg/mL.
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
Ivacaftor is approximately 99% bound to plasma proteins, primarily to albumin, and also to alpha 1-acid glycoprotein and human gamma-globulin.
BINDING
|
||
|
LIGAND->BINDER |
Glasdegib is 91% bound to human plasma proteins in vitro
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
The percentages ixabepilone bound to proteins at concentrations of 50, 500 and 5000 ng/mL were 76.6%, 72.0% and 67.1%, respectively. The protein binding of ixabepilone was not concentration dependent from 50 ng/mL to 5000 ng/mL.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
primarily to alpha-1-acid glycoprotein.
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
In vitro protein binding in human serum was 99.5% to 90.9% over an ibandronate concentration range of 2 to 10 ng/mL in one study and approximately 85.7% over a concentration range of 0.5 to 10 ng/mL in another study.
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
Human plasma protein binding of pretomanid is approximately 86.4% and is independent of drug concentration.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
Plasma protein binding is estimated to be 85 to 90% in the concentration range 1 to 230 nmol/L, independent of gender.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
in vivo
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
tezacaftor are approximately 99% bound to plasma proteins, primarily to albumin.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
BINDER->LIGAND |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
Plasma protein binding is independent on nelarabine concentrations.
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
The bound concentration increased slightly (,2%) as the concentration of 14C-rifapentine increased from 0.5 to 10 mg/ml. At concentrations above 10 mg/ml, protein binding did not appear to vary with increasing concentration.
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
For M16, protein binding was moderate and ranged from 82.6 to 85.7% 0.5 hr after avanafil administration.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
Plasma protein binding was greater than 99% and is independent of plasma concentrations.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
Reported not to bind to serum proteins
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
BINDER->LIGAND |
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
LDV is >99.8% bound to human plasma proteins when determined in vitro with equilibrium dialysis. In agreement with in vitro data, LDV protein binding was ≥ 98% in healthy subjects and in subjects with renal or hepatic impairment.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
Encorafenib is 86% bound to human plasma proteins and binding is not concentrationdependent
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
Unable to clear indoxyl sulfate in hemodialysis.
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
Abametapir plasm protein binding ranged from 91.3 – 92.3% and was concentration independent within the tested concentration range of 50 – 800 ng/mL.
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
Miglustat does not bind to plasma proteins.
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
Binding to human plasma proteins was low (approximately 22 %) and independent of the concentration of zoledronic acid.
BINDING
|
||
|
LIGAND->BINDER |
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 mg/ml).
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
Protein binding of lemborexant is approximately 93.2% to 94.0% between 29 ng/mL and 71 ng/mL.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
The protein binding of either piperacillin or tazobactam is unaffected by the presence of the other compound.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
Viloxazine is 76-82% bound to human plasma proteins over the blood concentration range of 0.5 mcg/mL to 10 mcg/mL.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
The in vitro protein binding in human plasma is below 8% for tipiracil.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
~90% Gilteritinib bound to plasma proteins, mainly albumin
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
SUB_CONCEPT->SUBSTANCE | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
independent of concentration
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
In vitro, protein binding of lorlatinib to human plasma proteins, including serum albumin and α1-acid glycoprotein, was 66% at a concentration of 2.4 μM.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
The human plasma protein binding of lasmiditan is approximately 55% to 60% and independent of concentration between 15 and 500 ng/mL.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
Plasma protein binding of alvimopan was independent of concentration over ranges observed clinically and averaged 80% .
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
Plasma protein binding is 25% to 30% in the concentration range from 37 to 1850 ng/mL.
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
Protein binding of selpercatinib is 97% in vitro and is independent of concentration.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
In vitro binding of gefitinib to human plasma proteins (serum albumin and α1-acid glycoprotein) is 90% and is independent of drug concentrations.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
Protein binding of tivozanib is ≥ 99%, primarily to albumin in vitro and is independent of
concentration.
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
BINDER->LIGAND | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
The protein binding of M1 is ~97% and is concentration independent.
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
The plasma protein binding of milnacipran is approximately 13% and is independent of the concentration (Study# M013).
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
The protein binding is concentration dependent and decreases with increasing telaprevir concentrations at all concentrations of human serum albumin (HSA) and α-1-acid glycoprotein (AAG). In addition, protein binding of telaprevir is affected by the concentration of HSA and AAG.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
Cenobamate mainly binds with human albumin protein and not with α1-acid glycoprotein.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
IN VITRO
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
The in vitro plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1.0 μg/mL).
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
Protein binding (primarily to serum albumin) of vericiguat is about 98%.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
In human plasma, the binding of R093877 increased at higher pH values. In the pH-range 7.1 to 7.7, the percentage bound increased from 23.3% to 35.5%
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
PARENT -> BIOSIMILAR | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
independent of concentration
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
decreases as concentration increases
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
In vitro, tazemetostat is 87.7 to 91.1% bound to human plasma proteins over the concentration range of 1 to 30 M.
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
In vitro, protein binding of talazoparib is 74% and is independent of talazoparib concentration.
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
Binding to the latter protein is saturable, and the drug displays nonlinear kinetics with respect to plasma concentration and clearance.
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
The binding of Relebactam to human plasma proteins is approxi mately22% and is independent ofconcentration at a range of 5 to 50 μM.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
The plasma protein to whichSN-38 predominantly binds is albumin.
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
In vitro, neratinib was highly bound (N 99 %) to human plasma proteins at clinical exposures. click to edit
BINDING
|
||
|
LIGAND->BINDER |
The mean plasma protein binding of vildagliptin in humans was low (9.3%) and also independent of concentration.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
Total in vitro protein binding is approximately 60% to 70% and is primarily due to human serum albumin. Protein binding is not modified in elderly subjects and in patients with hepatic impairment.
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
Zanubrutinib is approximately 94.2% bound to human plasma proteins in vitro, independent of concentration.
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
independent of capmatinib concentration
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER |
Binding of crizotinib to human plasma proteins in vitro is 91% and is independent of drug concentration.
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER |
|
||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER | |||
|
LIGAND->BINDER |
BINDING
|
||
|
LIGAND->BINDER | |||
|